MRI Characteristics of Ependymoblastoma: Results from 22 Centrally Reviewed Cases


doi: https://doi.org/10.3174/ajnr.A4002
http://www.ajnr.org/content/35/10/1996
ABSTRACT

BACKGROUND AND PURPOSE: Ependymoblastoma is a malignant embryonal tumor that develops in early childhood and has a dismal prognosis. Categorized by the World Health Organization as a subgroup of CNS-primitive neuroectodermal tumor, ependymoblastoma is histologically defined by “ependymoblastic rosettes.” Because it is so rare, little is known about specific MR imaging characteristics of ependymoblastoma. We systematically analyzed and discussed MR imaging features of ependymoblastoma in a series of 22 consecutive patients.

MATERIALS AND METHODS: Ependymoblastoma cases were obtained from the database of the German multicenter HIT trials between 2002 and 2013. All cases within this study were centrally reviewed for histopathology, MR imaging findings, and multimodal therapy. For systematic analysis of initial MR imaging scans at diagnosis, we applied standardized criteria for reference image evaluation of pediatric brain tumors.

RESULTS: Ependymoblastomas are large tumors with well-defined tumor margins, iso- to hyperintense signal on T2WI, and diffusion restriction. Contrast enhancement is variable, with a tendency to mild or moderate enhancement. Subarachnoid spread is common in ependymoblastoma but can be absent initially. There was a male preponderance (1.75:1 ratio) for ependymoblastoma in our cohort. Mean age at diagnosis was 2.1 years.

CONCLUSIONS: With this study, we add the largest case collection to the limited published database of MR imaging findings in ependymoblastoma, together with epidemiologic data. However, future studies are needed to systematically compare MR imaging findings of ependymoblastoma with other CNS-primitive neuroectodermal tumors and ependymoma, to delineate imaging criteria that might help distinguish these pediatric brain tumor entities.

ABBREVIATIONS: EBL = ependymoblastoma; PNET = primitive neuroectodermal tumor

According to the 2007 World Health Organization Classification of Tumors of the CNS, ependymoblastoma (EBL) is a grade IV embryonal tumor that can be categorized as a subgroup of primitive neuroectodermal tumor (PNET). The group of CNS-PNET can be further subdivided into CNS-neuroblastoma, CNS-ganglioneuroblastoma, NOS (not otherwise specified), and medulloblastoma. EBLs are highly aggressive tumors that occur mainly in young children, with rapid growth and craniospinal dissemination. The MR imaging appearance of EBL has been described in the literature as a large, well-demarcated but heterogeneous mass with variable contrast enhancement. Most of the tumors are located supratentorially, followed by infratentorial and spinal sites. Locations outside the CNS are exceptionally rare, with published cases of congenital sacrococcygeal or ovarian tumors.

First described by Bailey and Cushing in 1926 as an ependymal-derived entity, the exact definition of EBL has since generated some controversy among neuropathologists. Rubinstein later characterized EBLs as primitive neuroepithelial tumors of high cellularity that show numerous and characteristic “ependymoblastic rosettes.”

We want to contribute to this ongoing discussion with the first
systematic analysis of imaging characteristics of EBL. Differentiation from other primitive embryonal tumors (such as other CNS-PNET variants and medulloblastoma) by means of diagnostic imaging is challenging. Due to the rarity of this tumor, a systematic analysis of MR imaging features of EBL has not yet been performed. To determine specific diagnostic features, we report on imaging characteristics of 22 consecutive EBL cases that were collected from the prospective German Society of Pediatric Oncology and Hematology multicenter trials HIT91, HIT-SKK92, and HIT2000 (HIT is a German abbreviation for brain tumor), with central review for neuropathology, neuroradiology, and therapy.3,9,10

MATERIALS AND METHODS

Study Population
EBL cases were obtained from the database of the German multicenter HIT trials.11 Cases with histopathologic diagnosis of EBL, confirmed by central review in the Neuropathological Brain Tumor Reference Center of the German Society of Neuropathology and Neuroanatomy (T.P.), were included. Patients were diagnosed with EBL between the years 2002 and 2013. Two patients were initially diagnosed with EBL and were excluded because they showed negative immunohistochemistry for LIN28A, which has been recently proposed as a molecular marker for embryonal tumors with multilayered rosettes.12 We further excluded older cases where MR imaging (film copies) had not yet been digitized for image analysis. One patient from an external center was excluded because we lacked the initial MR imaging scans before surgery. A minimum of T1WI, T2WI, and contrast-enhanced T1WI in at least 2 different planes and without severe motion artifacts was required for cranial MR imaging scans in our study. Finally, 22 patients with sufficient preoperative cranial MR imaging scans were identified.

Image Analysis
For image analysis of our EBL cases, we used standardized MR imaging criteria according to the established routine evaluation of our Neuroradiological Reference Center for the HIT studies (as demonstrated in the On-line Table). Tumor diameter was measured in 3 dimensions (craniocaudal, left-right, anteroposterior; in cm), and tumor volume was calculated according to a common approximation formula (a × b × c × 0.5; in cm³). Tumor location was recorded (supratentorial, infratentorial, brain stem/diencephalon; related to cortex or ventricles, basal ganglia, or intraventricular location). T1- and T2-signal intensity of the tumor in relation to the signal intensity of the cerebral and cerebellar cortex was analyzed. We searched for possible cysts within the tumor, their localization (periphery, or other location) and size (small/ large cysts, with a diameter >1 cm being considered as large). Furthermore, we registered hemorrhagic changes, the homogeneity of the solid tumor and the delineation of the tumor mass from the adjacent tissue (well or ill-defined). We analyzed possible peritumoral edema and the extent of edema. Another criterion was the pattern of gadolinium enhancement within the tumors (intensity, percentage of enhancing volume, homogeneity), and possible restriction of EBL in DWI. We recorded tumor staging with possible macroscopic meningeal dissemination (stage M2–M3, according to the Chang classification of CNS-PNET13) at the time of diagnosis. Finally, CT scans (with focus on calcifications and tumor attenuation) and MR spectroscopy data were analyzed when provided by the external referring centers. With respect to the multicenter approach, MR imaging studies were obtained with MR scanners of different manufacturers at 0.5–3 T field strength. Image reading was performed by 2 neuroradiologists (M.W.-M. and J.N.) in consensus.

RESULTS

Study Population
A total of 22 consecutive patients with EBL (mean age at diagnosis 2.1 years, range 0.3–3.4 years) were analyzed for this study. There was a male preponderance with a 1.75:1 ratio (14 patients were male and 8 were female).

Image Analysis
Most EBLs were located supratentorially (16 of 22 cases, Fig 1), whereas 4 tumors were found infratentorially (Fig 2) and 2 tumors occurred in the brain stem/diencephalon. The MR imaging appearance of brain stem EBL has been recently described in detail by our group.14 Mean tumor volume was 114.7 cm³ (range 3–262 cm³). Cysts could be seen in 50% of the tumors (11 of 22), of which 6 tumors (55%) showed cysts in the tumor periphery. Regarding cyst size, only 2 of 11 tumors (18%) showed large cysts (as illustrated in Fig 3). In 17 of 22 EBL cases (77%), there were signs of intratumoral hemorrhage. There was also a tendency of inhomogeneous signal appearance in T1WI and T2WI: 17 tumors (77%) showed inhomogeneous or predominantly inhomogeneous signal, and only 2 tumors showed a homogeneous signal (9%; 3 tumors = 14% with predominantly homogeneous signal),

FIG 1. Typical MR imaging of EBL (patient 11), presenting as large hemispheric tumor mass. Note the well-delineated tumor margins and absence of surrounding edema. MR signal intensity is high in T2WI (A) and iso- to hypointense in T1WI (B). The tumor shows moderate enhancement of some parts after gadolinium administration (C). ADC map shows low signal (D, see also Fig 5B). Single-voxel MR spectroscopy (E) of the tumor with a choline:NAA ratio of 5:1, indicating high cellularity. There is a small peak for lactate at 1.3 ppm. A signal for lipids was not detected in this case (3T Trio; Siemens, Erlangen, Germany).
Small peritumoral edema can be found in T2WI (white arrows in Fig 1). Hemorrhage and/or calcifications. In T2WI, hypo- to hyperintense) could be found in T1WI, mainly due to partial hemorrhage and/or calcifications. In T2WI, hypo- to hyperintense signal intensities (ie, all types of signal intensities) were present in 19 of 22 cases (86%), reflecting inhomogeneous signal. The predominant T2 signal was isointense (12 cases, 55%) or hyperintense (10 cases, 45%). None of the tumors showed a predominant low (hypointense) signal intensity in T2WI. However, all analyzed tumors had sharp (19 of 22, 86%) or predominantly sharp (3 of 22, 14%) tumor margins (Fig 1) against the adjacent structures. Surrounding edema was present in only 2 of the cases with EBL (9%). DWI was available in 14 of 22 patients; in the remaining 8 cases, DWI was either not acquired or not submitted for central neuroradiologic review. All 14 tumors with available DWI showed high signal suspecting diffusion restriction, which could be confirmed by low ADC in 11 cases (Fig 1D, Fig 5B). In 3 cases, there was no ADC map available. Here, high signal in DWI with corresponding relatively low signal intensity in T2WI (not hyperintense) was considered as restricted diffusion. Hence, all 14 tumors (100%) with available DWI showed diffusion restriction. There were 17 tumors (77%) that presented with enhancement after intravenous gadolinium administration, with 6 tumors (35%) showing mild, 8 tumors (47%) moderate, and 3 tumors (18%) strong contrast enhancement. Enhancement was predominantly homogeneous in most enhancing tumors (13 cases, 76%), and completely homogeneous in 1 case (6%). A total of 2 tumors (12%) showed predominantly inhomogeneous contrast enhancement, and 1 tumor (6%) showed (completely) inhomogeneous enhancement. One tumor was found with 51%–75% gadolinium enhancement of the solid tumor component. Most EBLs (16 of 17, 94%) showed 26%–50% (7 cases) or 1%–25% (9 cases) solid tumor enhancement.

More than two-thirds of our EBL cases (17 of 22, or 77%) did not show imaging evidence of meningeal dissemination (indicating macroscopic dissemination) at presentation. In addition, we lacked spinal MR imaging scans for 4 cases and hence CNS macroscopic dissemination status remained unclear. At presentation, 6 of 7 patients (86%) with complete intracranial and spinal MR imaging datasets did not have positive imaging signs (M2 and/or M3) of meningeal dissemination. One patient had M3 stage (spinal CNS dissemination). Another patient presented with a solitary M2 stage (intracranial dissemination). However, spinal datasets were incomplete in this patient (according to our internal standard of MR acquisition parameters; see Discussion), in another 2 patients with proposed M3 stage, and in 2 patients with proposed M2 and M3 stage (intracranial and spinal dissemination). In the remaining patients, the exact status of possible CNS spread remained unclear from our neuroradiologic perspective. Single-voxel MR spectroscopy data were available for only 3 patients (14%), and showed an increase in the choline:NAA ratio up to 5:1, compared with normal brain tissue (Fig 1E). Additional CT scans were submitted in 5 of our 22 cases (23%), with EBL showing different solid components from hypodensification (minimum of 20 Hounsfield units) to hyperattenuation (maximum of 41 Hounsfield units), compared with cortex (Fig 6B, -D). In 3 cases (60%), there were calcifications within the tumors (60%). Typical histopathologic appearance of EBL is demonstrated in Fig 7.

**DISCUSSION**

**Study Population**

With this series comprising 22 MR imaging studies of EBL, we present detailed imaging characteristics of this rare pediatric CNS tumor entity. In addition to imaging features, our study also provides epidemiologic information of EBL. We found a male to female ratio of 1.75:1 in our patient collective. In all CNS-PNETs, this ratio has been reported with 1.4:1, according to the annual report of the German Childhood Cancer Registry. The mean age

---

**FIG 2.** Infratentorial EBL (patient 7) of the fourth ventricle with marked displacement of the brain stem (A). T2 signal is predominantly inhomogeneous. No surrounding edema is present (B). Methemoglobin as a sign of intratumoral hemorrhage (white arrow in C). This tumor does not enhance after contrast administration (D) [1.5T Symphony; Siemens].

**FIG 3.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 4.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 5.** Infratentorial EBL (patient 7) of the fourth ventricle with marked displacement of the brain stem (A). T2 signal is predominantly inhomogeneous. No surrounding edema is present (B). Methemoglobin as a sign of intratumoral hemorrhage (white arrow in C). This tumor does not enhance after contrast administration (D) [1.5T Symphony; Siemens].

---

**FIG 6.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 7.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 8.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 9.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 10.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 11.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 12.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 13.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].

---

**FIG 14.** Hemispheric EBL (patient 6) with inhomogeneous signal and moderate contrast enhancement (yellow arrow in A). Cystic components of variable size are present in the tumor (white arrows in A and B). Small peritumoral edema can be found in T2WI (white arrowhead in B). Note there is significant mass effect with midline shift. Tumor margins are less defined in some areas compared with patient II (Fig 1) [1.5T Symphony; Siemens].
at diagnosis for all CNS-PNETs in this registry was 4 years 0
months, whereas mean age at diagnosis of EBL was 2.1 years in our
study. Thus, it seems that there might be a male preponderance
for EBL and other CNS-PNETs (with a slightly stronger tendency
for EBL in males), and a younger age at diagnosis in EBL, com-
pared with other CNS-PNETs. There are currently no data avail-
able in the literature about mean age at diagnosis, incidence, or
sex and race predisposition of EBL. According to the Surveillance,
Epidemiology and End-Results database, neither sex nor race was
a predictor for CNS-PNET development.16

Image Analysis
To date, only very limited MR imaging data are available from few
case reports.3,17-21 Histologically designated as a subgroup of
CNS-PNET, EBL seems to share imaging features with (other)
CNS-PNETs. On MR imaging scans, EBL and other CNS-PNETs
appear as large, heterogeneous tumor masses with iso- to hyper-
tense signal to gray matter on T2WI, pointing to increased cel-
lularity.22,23 This is further supported by restricted diffusion
(100% of our EBL cases) and decreased ADC, which has been
reported for other CNS-PNETs as well.24 In addition, necrosis
and hemorrhage are common in CNS-PNET and in our EBL cases
(77%). The solid tumor component of CNS-PNET has been de-
scribed with avid heterogeneous gadolinium enhancement in the
literature.25 For EBL, we found mild to moderate enhancement in
most cases (6 and 8 of 22, respectively). Only 3 cases showed
strong enhancement, whereas 5 patients did not show any con-
trast enhancement. Surrounding edema seems to be only minimal
in both EBL (9% in our study) and other CNS-PNETs.23 Calcifi-
cations are seen in up to 70% of CNS-PNETs, with iso- to hyper-
attenuating appearance in CT.22,26 This is relatively consistent
with our EBL cases (60% calcifications), though we analyzed only
5 tumors with available CT scans. MR spectroscopy findings in
CNS-PNET are characterized by marked elevation of taurine and
choline levels with low creatine.26,27 We are the first to demon-
strate MR spectroscopy findings in EBL, with a high choline:NAA
ratio pointing to increased cell turnover, similar to CNS-PNET. It
is not yet clear whether MR spectroscopy might be useful to dis-
tinguish CNS-PNET variants from EBL and other brain tumors in
the clinical setting. Considering evolving techniques such as per-
fusion MR imaging and DTI, we lack data to further characterize
EBL. Perfusion MR imaging in CNS-PNET showed increased rel-
ative CBV values that might result from vascular endothelial hy-
perplasia and increased permeability, as seen in other high-grade
FIG 7. Typical histopathologic finding of EBL (patient 1) with ependymoblastic rosettes (black arrows).

tumor termed an embryonal tumor with abundant neuropil and true rosettes (ETANTR) has been proposed as a novel CNS tumor entity by some authors. They argue that combined features of EBL and neuroblastoma, containing multilayered ependymoblastic rosettes (“true” rosettes), define a separate novel histologic tumor entity with poor outcome. However, this largely overlaps with the original descriptions by Rubinstein, probably representing the identical phenotype and diagnosis. Recent molecular studies further clearly demonstrate that tumors diagnosed as EBL, ETANTR, or embryonal tumors with multilayered rosettes carry identical, highly specific chromosomal alterations (amplification at 19q and/or gain of chromosome 2). EBL and the proposed “novel” entities therefore represent a single embryonal tumor entity (defined as EBL according to the 2007 World Health Organization classification). Consequently, all 22 tumors of our case collection were designated EBL by central neuropathologic review (T.P.). We intend to contribute to this ongoing discussion with the first systematic analysis of imaging characteristics of EBL.

CONCLUSIONS

The case series presented here is the largest collection of MR imaging data for EBL to date. Imaging appearance of EBL seems to share features with other pediatric embryonal CNS tumors. However, a systematic analysis that compares imaging findings of EBL with (other) CNS-PNETs and ependymoma is needed to evaluate possible differences in image appearance of these entities.

ACKNOWLEDGMENTS

This work was supported by the Deutsche Kinderkrebsstiftung (German Childhood Cancer Foundation). We furthermore thank Emily Decelle and György A. Homola for their help with manuscript editing.

REFERENCES

2. Osborn AG. Osborn’s Brain: Imaging, Pathology, and Anatomy. Salt Lake City: Amirsys; 2013:573–75
6. Bailey P, Cushing H. A Classification of the Tumors of the Glioma...
8. Rubinstein LJ. The definition of the ependymoblastoma. Arch Pathol 1970;90:35–45